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Mobile health (mHealth) interventions are a promising tool in providing digitally mediated integrative care. They can extend
care outside of the clinic by providing reminders to take medications, assisting in managing symptoms, and supporting
healthy behaviors including physical activity, healthy eating, and stress management. mHealth interventions can adapt the
delivery of care across time in order to optimize treatment effectiveness. Yet there exists limited empirical evidence useful
to the development of adaptive mHealth interventions. This article describes a new randomized trial design, the Micro-
Randomized Trial (MRT), for informing the development of mHealth interventions. We provide examples of scientific ques-
tions important to the development of an mHealth intervention, and describe how these questions can be answered using
an MRT.
There is an increasing interest in the use of mobile devices to pro-
vide digitally mediated integrated healthcare. This is because
many digital technologies such as smartphones and wearable
trackers are deeply integrated into everyday life and thus might
be a low-barrier way to improve medical care. For example, digital
technologies could help address adherence to prescribed medica-
tions, as well as provide support for self-care behaviors such as
engaging in sufficient physical activity. Although not considered
as a replacement for face-to-face interactions, mobile devices are
thought to have the potential to extend the reach of healthcare,
making treatments more accessible and scalable.1,2 Mobile health
(mHealth) interventions have been developed, tested, and evalu-
ated in various health domains, including weight management,3
smoking cessation,4 and mental health.5 It has also become possi-
ble to seek approval for mHealth interventions from the US
Food and Drug Administration (FDA), where recently the FDA
approved a prescription-only “digital therapeutic” for substance
abuse.6
In mHealth, treatments, which are typically in the form of
reminders, messages, and supportive content, can either be “pushed”
or “pulled.” Pull treatments are initiated by the individual; for
example, in FOCUS,7 an mHealth intervention that provides ill-
ness management support to individuals with schizophrenia,
patients can access a collection of self-management strategies (e.g.,
focusing on medication adherence, sleep, or mood regulation) on
their mobile device at any time they choose. Pull treatments require
that individuals are able to recognize when they need support, and
are motivated to seek out that support. Alternatively, push treat-
ments are initiated by the mHealth intervention. Treatment is
intended to be delivered to the individual at moments when it is
best poised to be effective; when treatment is most likely to prevent
unwanted behaviors or support the achievement of desired health
behaviors. Adapting the timing and content of the push treatments
in order to optimize effectiveness is of great importance, because
push treatments interrupt the individual, and can potentially lead
to burden8–10 and disengagement.11–13 There is limited empirical
evidence available to inform the development of these kinds of
intervention components.14–17 Thus, it is particularly important to
assess when to deliver a push treatment.
One method for understanding when both push and pull treat-
ments are effective is to use a newer type of trial design, the
Micro-Randomized Trial (MRT). MRTs are currently in use to
inform the development of mHealth interventions including
interventions that target weight management, physical activity,
smoking cessation,18 and patient engagement19 (see the MRT
website for more details).20 This article describes how MRTs can
be used to assess the effectiveness of treatments in mHealth inter-
ventions; here we focus on push treatments. We discuss the scien-
tific questions that data from an MRT is able to address in
reference to MRTs currently in the field. We then provide an
overview of the MRT and define key terms, then we walk
through an example of how data are collected and analyzed to
address a scientific question regarding the delivery of an mHealth
treatment from a current MRT. In conclusion, we compare the
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MRT to N-of-1 and single case experimental designs, as well as
randomized clinical trials.
CRITICAL QUESTIONS IN THE DEVELOPMENT OF AN
MHEALTH INTERVENTION
There are many different scientific questions that might need to
be addressed when developing an mHealth intervention. Dis-
cussed below is a small selection of possible research questions,
where MRTs may focus on one or many of the questions below
(see Klasjna et al. for more examples).21
First, a researcher needs to know if it is worthwhile to deliver a
treatment at all. For example, suppose a researcher wants to
know if sending a text message to a patient’s phone to remind
them to take their medication increases medication adherence on
that day. Daily medication adherence could be measured using an
electronic pill bottle that records when the bottle is opened.
Whether or how often the pill bottle was opened after sending a
reminder, compared with whether or how often the pill bottle
was opened when a reminder was not sent, will provide informa-
tion about the effect the reminder has on adherence. Consider
another example from the MRT of the application Heart-
Steps,21–24 an mHealth intervention designed to increase physical
activity in sedentary adults. In this intervention the smartphone
may push activity suggestions tailored to the time of day, individ-
uals’ current location, and current weather conditions. This tai-
loring is designed to make the activity suggestions actionable in
the individual’s current context. A first question to address is
whether pushing the tailored activity suggestions results in an
increase in participants’ step count in the 30 minutes following
the delivery of a suggestion, compared with not pushing a sugges-
tion. Addressing these types of questions provides a first indica-
tion of whether or not the push treatment should be included in
the mHealth intervention.
There are often multiple different kinds of treatments that
could be delivered as part of an mHealth intervention, and a
researcher might want to know which of them is more effective.
Consider an mHealth intervention to target adherence to a pre-
ventative medication, where the lack of short-term benefits may
lead to negative beliefs about the medication’s efficacy. In behav-
ioral research there is evidence that making the long-term bene-
fits of a decision more salient in the moment can prevent
individuals from overvaluing the short-term impacts of treat-
ment.25–27 Thus, a researcher might want to compare the effect
on daily adherence of a generic reminder message with a
reminder message that includes content referencing long-term
benefits of taking the medication. Alternately, consider a mobile
intervention designed to optimize the delivery of prompts (via
push notifications) to improve self-monitoring of dietary intake
among obese adults. Here an important question would be
whether an evening notification that prompts participants to
plan for how they will reach their calorie goal the following day
has a different effect if this evening planning demands a high
level of effort (high burden) or a low level of effort (low burden)
on the part of the participant. To address this question, success
achieving calorie goals when participants are prompted to engage
in “structured,” low burden, evening planning (e.g., choosing a
plan from a dropdown menu) can be compared with success
achieving calorie goals when participants are prompted to engage
in “unstructured,” higher burden evening planning (e.g., writing
out their plan in a provided text box). Here, addressing these
types of questions can be used to inform decisions about what
type of push treatments to include as part of an mHealth
intervention.
The significance of mHealth interventions, as previously dis-
cussed, is partially attributed to the ability to integrate them into
individuals’ everyday lives. As a result, researchers may need to
understand how the success of treatments depends on characteris-
tics of the contexts in which they are delivered. The Sense2Stop
MRT is investigating whether the effect of a stress-regulation
prompt to support smoking cessation is more effective when the
individual is detected as being stressed, compared with when they
are not stressed.18 Furthermore, suppose a researcher is develop-
ing an mHealth intervention for individuals with sickle cell dis-
ease (SCD) to help them remember to drink water. Hydration
has been shown to be a critical determinant of pain experience
and health-related outcomes in SCD.28–30 Evidence suggests that
there are certain conditions under which staying hydrated is of
particular importance, such as a change in temperature31 or
recent levels of physical activity.32 Therefore, a researcher might
ask how these factors influence the effectiveness of a hydration
reminder to increase the number of ounces of water consumed
by the patient in the following hour. The contextual factors that
relate to the effectiveness of treatment might also include individ-
uals’ responses to past treatments. In the example of hydration
reminders for patients with SCD, a researcher might ask if the
effect of delivering a reminder varies by the ounces of water
patients consumed in response to previous reminders. Addressing
these types of questions related to under what conditions it is
most useful to provide treatments can also be used to develop an
mHealth intervention.
mHealth interventions can be designed to provide long-term
treatment over the course of weeks, months, or even years. There-
fore, it is important to understand how the effects of different
treatments will change as the mHealth intervention progresses.
For example, a researcher might ask if the effect of a daily medica-
tion reminder on adherence dissipates with time due to habitua-
tion to the messages.33,34 It may also be important to understand
the best way to sequence the delivery of different treatments.
Consider again the evening planning prompts aimed at increasing
self-monitoring of dietary intake, where individuals plan how to
meet their calorie goal for the next day. There may be scientific
questions concerning how the effectiveness of the evening plan-
ning prompt might be impacted by the delivery of other treat-
ments that are provided as part of the same mHealth
intervention, such as a mid-day prompt to reminding participants
to monitor their dietary intake. Researchers might want to know
whether the unstructured (higher burden) evening planning is
more effective (compared with the lower burden structured plan-
ning) if the mid-day reminder was framed in a way that empha-
sized the individual’s core values (i.e., “value-based”). This is a
scientific question concerning the optimal sequencing of these
two treatments, specifically if value-based reminders build the
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foundation for the effectiveness of unstructured planning by
increasing motivation to invest effort in achieving weight loss
goals. Or alternatively, there might be important questions about
mHealth interventions that involve sequences of treatments
focusing on different aspects of a disorder. Consider the develop-
ment of an mHealth intervention for smoking cessation that
incorporates mindfulness exercises as well as financial incentives
to support an individual in abstaining from smoking. It may be
that financial incentives are most useful early in the quit attempt,
whereas prompts to remind individuals to practice mindfulness
exercises might be most useful later in recovery. In this case, data
to address which treatment should be delivered and when would
be useful in designing an mHealth intervention that is intended
to be used over a longer time period. Addressing these kinds of
questions can inform when during the course of an mHealth
intervention delivering certain treatments will be most effective.
In summary, answering questions regarding what kind of treat-
ment, when, and for whom it is most beneficial is critical to the
design of mHealth interventions. This is particularly important if
the mHealth intervention is to include push components, as
these can be burdensome, leading to disengagement.8–13 We now
describe the MRT design and how it can provide data to answer
such questions.
THE MICRO-RANDOMIZED TRIAL
MRTs can be used to inform the development of an mHealth
intervention in which treatment components (e.g., treatment
pushes such as activity suggestions) may be delivered multiple
times during the day or week, and are designed to impact a long-
term outcome by impacting a near-term proximal outcome. For
example, as discussed earlier, HeartSteps is an mHealth interven-
tion in which activity suggestions may be delivered five times per
day, aiming to help sedentary adults achieve and maintain recom-
mended levels of moderate-intensity physical activity (distal out-
come) by increasing an individual’s physical activity in the 30
minutes following the delivery of an activity suggestion (proximal
outcome).21–24 An MRT can be used to inform the construction
of an effective mHealth intervention by providing data to address
questions regarding the assessment of whether the treatments will
impact the proximal outcome(s), how treatment effects vary over
time, and how to effectively sequence treatments.
The scientific questions outlined above can be addressed with
an MRT through the randomization of individuals to treatment
options each time a treatment component might be delivered.
This micro-randomization may result in hundreds or even thou-
sands of randomizations per individual during a study. For exam-
ple, in the HeartSteps MRT participants were randomized to
three treatment options five times per day: an antisedentary activ-
ity suggestion, a walking activity suggestion, or no suggestion.
The activity suggestions were designed to have a momentary
effect on step count; thus, the proximal outcome is total step
count in the 30 minutes following delivery of the suggestion. In
this example, the set of different treatment options includes not
delivering treatment (i.e., not delivering an activity suggestion to
reduce burden). Alternatively, the set of treatment options within
a component can include only multiple active treatment options,
where, for example, every evening an individual is randomized to
always receive one of two types of evening planning prompts
(structured vs. unstructured). The randomization provides data
that can be used to estimate the causal effect of treatment compo-
nents like the activity suggestions because it ensures that known
and unknown factors that may influence a participant’s response
to a suggestion are distributed evenly between the treatment
options.
In an MRT, participants are randomized between treatment
options at each decision point, which are the moments in time at
which a treatment component might be delivered. How often
participants receive a particular treatment at each decision point
is determined by the randomization probabilities defined for each
treatment option. The timing of decision points, as well as the
probability of a participant receiving each of the treatment
options at each decision point, are motivated by scientific and
practical considerations concerning when and how often provid-
ing treatment is most likely to be effective. Consider the timing
of decision points for the activity suggestions in the HeartSteps
MRT, described above. Prior studies indicated that sedentary
individuals with standard, weekday employment tend to have the
highest within-person variance in step count at five times: pre-
morning commute, midday, midafternoon, evening commute,
and after dinner.21 This higher variance indicates that the indi-
viduals might be more responsive to an activity suggestion during
these times. Thus, these five times each day were used as the deci-
sion points in HeartSteps for the activity suggestion component.
In order to reduce burden and prevent disengagement with the
intervention, researchers wanted participants to only receive an
activity suggestion at approximately two of the five decision
points each day. Researchers also wanted participants to have an
equal chance of receiving the walking activity suggestion and the
antisedentary activity suggestion. Therefore, at each of the five
decision points, participants had a 0.3 probability of receiving an
antisedentary activity suggestion, a 0.3 probability of receiving a
walking activity suggestion, and a 0.4 probability of receiving no
suggestion. In other cases, an MRT might be designed to have
more decision points where there is a lower probability of being
assigned to treatment, or fewer decision points with a higher
probability of participants being assigned to treatment. These
choices are always driven by scientific evidence related to when
and how often a treatment is likely to have the most significant
impact on the intended proximal outcome.
A more complex MRT might provide data concerning multi-
ple treatment components. There can be different decision points
for each treatment component. For example, the BariFit MRT
(see the fourth diagram on the MRT website)20 includes an
“activity goal schedule” component in addition to the “activity
suggestion” component. As in HeartSteps, the “activity sug-
gestion” component in BariFit includes three treatment options
(delivering one of two types of tailored activity suggestions, and
not delivering an activity suggestion), which are assigned at five
different decision points each day. However, the “activity goal
schedule” treatment component includes two options: daily activ-
ity goal with no rest days, vs. daily activity goals including rest
days. The treatment options for this component are assigned to
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individuals at the beginning of the study; that is, there is only
one decision point for the activity goal schedule component,
where each individual is randomized to receive either type of goal
schedule for the duration of the study. An MRT can be designed
to estimate the effectiveness of multiple different intervention
components, where randomization and delivery occurs at differ-
ent points in the study.
In addition to addressing scientific questions concerning what
treatment options are generally worthwhile, randomization also
assists in ascertaining if certain conditions influence the effective-
ness of treatment components. For example, MRT data can be
used to investigate if an activity suggestion delivered as part of
the HeartSteps intervention is more successful at increasing phys-
ical activity and is perceived as less burdensome under certain cir-
cumstances, such as when an individual is less busy (e.g., based on
his/her entries in their smartphone calendar) than otherwise.
Therefore, MRTs assist researchers in deciding when it is most
worthwhile to interrupt the individual to provide treatment.
The randomization in MRTs can be used to investigate
whether and how the effect of treatments may vary over time.
For example, data from an MRT can be used to address questions
such as whether the effect of delivering an activity suggestion dis-
sipates with time. Data from an MRT can also inform the
sequencing of treatment components. Consider again our exam-
ple of an MRT that aims to increase self-monitoring of dietary
intake among obese adults, where participants are randomized
every evening to the two types of planning prompts: structured
(i.e., low burden evening planning) vs. unstructured (higher bur-
den evening planning). This MRT could also include a midday
randomization to reminders that encourage self-monitoring of
dietary intake, where every day the individual is randomized to
either 1) a generic reminder; 2) a value-based reminder; or 3) no
reminder. These data can be used to investigate whether the
unstructured (higher-burden) evening planning is more effective
(compared with the lower-burden structured planning) if a value-
based reminder was delivered at midday on the same day. This
scientific question concerns the sequence of treatment options,
and is motivated by the conjecture that midday value-based
reminders may build the foundation for the effectiveness of the
unstructured evening planning prompt by increasing motivation
to invest effort in achieving weight loss goals.
We have described how an MRT can be used to address ques-
tions to inform the development of mHealth interventions, ques-
tions including what treatments are effective, and how their
effectiveness may vary with respect to the context of delivery,
time, and sequencing of treatment. The scientific questions in
the current MRTs we have referenced are addressed using a gen-
eralization of the common generalized estimating equation
(GEE) analysis method to test for causal effects of treatment
components, and moderation effects of time-varying factors.35–37
For researchers interested in running an MRT there are open
source tools available for power planning and sample size calcula-
tions.38–40 Additionally, we walk through an example below of
how the data generated by an MRT can be used to answer scien-
tific questions about the delivery of mHealth treatments.
EVALUATING THE EFFECTIVENESS OF DAILY ACTIVITY
PLANNING IN HEARTSTEPS
In order to demonstrate how an MRT can be used to generate
data for the optimization of mobile health interventions, we use
an example from the HeartSteps MRT. The goal of HeartSteps
was to develop an mHealth intervention to increase physical
activity levels in sedentary adults. Accordingly, the MRT is
designed to answer scientific questions with respect to two inter-
vention components: activity suggestions, and daily activity plan-
ning, including whether or not these interventions are effective,
in what contexts delivering these interventions is beneficial, and
how the effectiveness of these interventions might change over
time. For simplicity, we will focus our example on the daily activ-
ity planning. First, we describe the daily planning intervention
component delivered as part of the HeartSteps MRT, how it was
implemented, and the data the MRT generated. Then we
describe how these data would be analyzed in order to estimate
the treatment effect of the daily activity planning intervention
component, as well as moderation effects.
As discussed above, an MRT provides data to inform the devel-
opment of mobile health interventions by randomizing partici-
pants to different treatment options at multiple decisions points
for the duration of a study, usually across a period of weeks or
months. In the HeartSteps MRT, the daily activity planning was
an intervention component where participants were randomized
to receive one of the two treatment options at a daily decision
point every evening: 1) a prompt to make a plan for how they
were going to be active the next day, or 2) no prompt. Partici-
pants had a 50% chance of receiving either of these treatment
options at every daily decision point. This intervention compo-
nent was motivated by behavioral science suggesting that specify-
ing intentions for how to implement behavioral goals increases
the ease of engaging in that behavior.42 Thus, the proximal out-
come for the daily planning intervention component was the
total number of steps taken the day following being randomized
to receive one of these two treatment options. This proximal out-
come was measured with a wristband activity tracker that partici-
pants wore for the duration of the study that monitored their
steps throughout the day. In the HeartSteps MRT, 37 individuals
were randomized with a 0.5 probability to either receive daily
activity planning or no activity planning, once a day, for 42 days.
Therefore, the data generated by the HeartSteps MRT with
respect to the daily activity planning comprised daily step counts
for 37 individuals across the 42-day study, which can be used to
estimate the effect of receiving a daily activity planning prompt
on step counts for the following day.
Data from an MRT can be analyzed with a generalization of
regression specifically developed to ensure unbiased estimates of
causal effects of time-varying treatments. Proximal effects are
defined in terms of the potential outcomes, and estimated using a
GEE approach with an independent correlation matrix (see Bor-
uvka et al. for more details).35 These analyses pool time-varying,
longitudinal data across all study participants. Now consider the
daily activity planning in HeartSteps. Here, the MRT is designed
to investigate whether there is an effect of providing a daily activ-
ity planning prompt vs. no prompt on the next day step count.
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Let t1 denote timepoints at which an individual may or may not
receive a daily planning prompt; t1 ranges from 1 to 42 (42
days*1 decision point per day). The focus is on the marginal
effect of delivering an activity planning prompt (vs. no prompt)
at t1 on step count at the next day tt11 (proximal effect). To test
whether there is an average activity planning prompt effect on
the next-day step count at any point during the study, we can use
a model that includes an intercept and an indicator variable for
activity planning prompt (51) vs. no prompt (5–1). In order to
investigate potential moderators of this treatment effect (e.g., day
of the study at t1, weather at t1) the model above can be extended
to include a covariate-by-prompt interaction term. Estimating
the proximal effect of the daily activity planning prompt on par-
ticipants’ step count the next day provides information about
whether or not it should be included as part of an mHealth inter-
vention to increase physical activity in sedentary adults. Investi-
gating the moderation effects of factors such as day of study and
weather conditions can provide guidance for when and in what
contexts delivering the daily activity planning prompt would be
most effective.
DISCUSSION
We described the use of an MRT in developing mHealth inter-
ventions to provide digitally integrated care. We provided exam-
ples of scientific questions relevant to the delivery of this care,
and described how the data generated by an MRT can be used to
answer these kinds of questions in order to optimize the effective-
ness of treatments delivered as part of mHealth interventions.
We conclude with a discussion of how the MRT compares to
other types of trial designs.
MRTs may appear very similar to N-of-1 studies or Single
Case Experimental Designs (SCED) used in the behavioral scien-
ces.42 In both of these latter designs a participant undergoes a
series of intervention episodes; in each episode a different inter-
vention package may be (randomly) assigned. These designs are
very similar, but each are appropriate for different scientific goals.
Traditionally, N-of-1 studies are used to estimate individual-level
causal effects of different interventions,43 and are best suited to
assess intervention effects in settings in which individuals can
serve as their own control, and when it is too expensive or too
difficult to recruit a large number of participants.44–46 In these
cases, individuals can serve as their own control if there are no
carryover effects of treatments and the “washout period” between
treatment episodes is sufficiently long as to allow the effect of the
prior treatment to dissipate. Here the scientific goal is the same
as a classical randomized trial: to determine whether intervention
package (A) is better than another intervention package (B).”
In comparison, the MRT is designed to provide data to address
dynamic questions about sequences of individual treatment com-
ponents that are part of an intervention package. For example,
researchers would use an MRT if they are interested in the carry-
over effects, specifically, how delivering one treatment directly
before another type of treatment may change the effectiveness of
the intervention. MRTs are also most appropriate in settings in
which time under treatment may be a significant factor in under-
standing the effect of subsequent treatment, and where
developing an mHealth intervention requires understanding how
treatment may need to be adapted across time in response to
changes to incoming information about the individual’s current
state. It is important to note that MRTs and N-of-1 studies can
appear similar, particularly in cases where multiple N-of-1 studies
are combined.47–49 We expect that in the future there will be
increasing convergence between MRTs and N-of-1 studies, par-
ticularly in the case of evaluating technology-based interventions
(see Dallery et al. for a review).50
A researcher would not choose an MRT design if they wanted
to assess an intervention package as a whole. The MRT cannot
replace the standard randomized clinical trial in which an
mHealth intervention might be contrasted with standard care or
a suitable control in terms of the distal outcome. Rather, the
MRT is akin to a factorial design used to optimize and build
multicomponent interventions, where they are best suited to
address questions regarding the effectiveness of the individual
treatment components that make up an mHealth intervention.51
This allows for the discarding of less effective, more burdensome
components, as well as an understanding of when and in what
contexts delivering different treatments will have the greatest
impact. After an MRT provides guidance for how to optimize
the components in an intervention package, an evaluation on the
basis of the distal outcome would occur in a future randomized
clinical trial.
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